EP
TEVA icon

Essential Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Essential Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08K Hold
32
– – ﹤0.01% 2210
2026
Q1 		$964 Hold
32
– – ﹤0.01% 2259
2025
Q4 		$999 Sell
32
-77
-71% -$1.9K ﹤0.01% 2031
2025
Q3 		$2.2K Buy
+109
New +$1.91K ﹤0.01% 1765

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Essential Partners's TEVA Position: Q2 2026 in Review

Essential Partners held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 32 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

Essential Partners first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.2K in Q3 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Essential Partners held 32 shares of Teva Pharmaceuticals worth $1.08K as of Q2 2026.
  • Essential Partners left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2210 holding.
  • Essential Partners first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Teva Pharmaceuticals position peaked at $2.2K in Q3 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.